Analysts' Top 5 Price Targets of September 4, 2025
Reading Time: 4 minutes
MannKind [US56400P7069] H.C. Wainwright reaffirms Buy rating and raises the price target from $9 to $11 (100% upside potential) The increase in price target is primarily based on the success of the TETON-2 study for Tyvaso inhalation solution from United Therapeutics , a partner company of MannKind . In the TETON-2 study, Tyvaso demonstrated a significant improvement in absolute forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF). According to Wainwright, the compelling study data eliminates a "significant...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
